CorMedix Inc. (CRMD) Reports Q1 2026 Results

On May 14, 2026, CorMedix Inc. (NASDAQ:CRMD) reported Q1 nett gross of $127.4 cardinal and nett income of $38.6 cardinal with adjusted EBITDA of $70.0 million. The steadfast said DefenCath contributed $97.5 cardinal successful gross with higher outpatient dialysis utilization and a $9.0 cardinal favorable estimation change. The acquired Melinta portfolio added $29.9 million.

The institution raised its 2026 guidance, projecting gross betwixt $325 cardinal and $345 cardinal and adjusted EBITDA to $115 million-$135 million. The corp reported currency and short-term investments of $178.1 cardinal arsenic of March 31, 2026.

Chairman and CEO Joseph Todisco said CorMedix entered the twelvemonth with "strong momentum" and that DefenCath "continues to transcend expectations" contempt pending TDAPA expiration. He besides noted advancement successful late-stage programs, including REZZAYO, with the institution preparing an FDA submission successful the 2nd fractional of 2026. It targets a imaginable expanded motorboat successful 2027.

CorMedix Inc. (NASDAQ:CRMD) is simply a pharmaceutical and aesculapian instrumentality steadfast that makes and markets therapeutic solutions for the prevention and attraction of diseases and conditions.

While we admit the imaginable of CRMD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.